Court Opinion

ID: 8483904
Source: CourtListenerOpinion
Date Created: 2022-11-15 18:01:43.210937+00
Date Added: 2024-06-11T16:49:49.687665
License: Public Domain

In the United States Court of Federal Claims
                      OFFICE OF SPECIAL MASTERS

*************************
DAVID BORDEN, as Personal                    *
Representative of the Estate of Mona         *
Borden,                                      *      No. 19-1526V
                                             *
                   Petitioner,               *      Special Master Christian J.
                                             *      Moran
                                             *
v.                                           *      Filed: October 6, 2022
                                             *
SECRETARY OF HEALTH                          *      Severity; residual effect;
AND HUMAN SERVICES,                          *      bone marrow biopsy; bone
                                             *      marrow aspiration; surgical
                                             *      intervention; thrombocytopenic
                                             *      purpura; influenza (“flu”)
                   Respondent.               *      vaccine.
*************************
Mark T. Sadaka, Law Offices of Sadaka Associates, LLC, Englewood, NJ, for
Petitioner;
Julia M. Collison, United States Dep’t of Justice, Washington, DC, for
Respondent.

           PUBLISHED DECISION DENYING ENTITLEMENT1

       Ms. Borden alleged that the influenza (“flu”) vaccine she received on
October 3, 2016 caused her to suffer from thrombocytopenic purpura. Pet., filed
Oct. 2, 2019. However, for the reasons explained below, petitioner has not

      1
        The E-Government Act, 44 U.S.C. § 3501 note (2012) (Federal
Management and Promotion of Electronic Government Services), requires that the
Court post this decision on its website. This posting will make the decision
available to anyone with the internet. Pursuant to Vaccine Rule 18(b), the parties
have 14 days to file a motion proposing redaction of medical information or other
information described in 42 U.S.C. § 300aa-12(d)(4). Any redactions ordered by
the special master will appear in the document posted on the website.
demonstrated that Ms. Borden’s injury satisfies the Vaccine Act’s (“the Act”)
severity requirement. Accordingly, petitioner is not entitled to compensation.

   I.       Procedural History
      Ms. Borden filed her petition on October 2, 2019. The petition alleges Ms.
Borden received a flu vaccine on October 3, 2016 and that, shortly thereafter, she
began to suffer from thrombocytopenic purpura. Pet. at 1. She claimed the
condition was either caused-in-fact by the vaccination or significantly aggravated
by the vaccine. Id.
      Ms. Borden filed medical records on October 14, 2019 and February 11,
2020. She filed an affidavit on April 13, 2020, clarifying her position. Additional
medical records were filed on May 20, 2020 and December 15, 2020.
      Anticipating the potential for the parties to retain experts, the undersigned
issued draft expert instructions on December 22, 2020. However, the parties
ultimately did not file any expert reports.
       The Secretary filed his Rule 4 Report on January 6, 2021, contesting
entitlement.2 The Secretary identified several problems with Ms. Borden’s case.
Ms. Borden had not filed an expert report supporting her claim, and the onset of
her symptoms was outside the Table’s range for which a presumption of causation
would be appropriate for thrombocytopenic purpura after an MMR vaccine.
Resp’t’s Rep., filed Jan. 6, 2021, at 10. Another major issue, the Secretary argued,
was that Ms. Borden’s clinical course did not satisfy the Act’s severity
requirement. Id. This issue ultimately defined this case.
       In light of the issues raised by the Secretary, Ms. Borden proposed a fact
hearing to gather testimony from available witnesses to address the severity of her
injury. Pet’r’s Status Rep., filed Jan. 21, 2021. The undersigned issued an order

        2
         In his Rule 4 Report, the Secretary describes Ms. Borden’s condition as
“idiopathic thrombocytopenia purpura” (“ITP”). One of Ms. Borden’s physicians
similarly concluded her thrombocytopenia purpura was idiopathic. However, Ms.
Borden’s petition claims she suffered from thrombocytopenia purpura due to a
vaccine, meaning it was not idiopathic, according to her.
       The Vaccine Injury Table notes that immune thrombocytopenic purpura was
formerly called idiopathic thrombocytopenic purpura. These terms would reduce
to the same acronym – ITP. To avoid confusion, the full name of the condition
will be spelled out.
                                          2
the following day, noting that testimonial assertions may be insufficient to fulfill
the Act’s severity requirement. See Order, issued Jan. 22, 2021 (citing Armbruster
v. Sec’y of Health & Hum. Servs., No. 17-1856, 2020 WL 3833396, at *11-12
(Fed. Cl. Spec. Mstr. Feb. 5, 2020)). As such, the undersigned explained he was
more interested in hearing arguments supporting Ms. Borden’s position that she
did meet the severity requirement. She was ordered to file a brief addressing
precedent about severity and explaining why her case fulfilled the severity
requirement.
       Ms. Borden filed her brief on February 16, 2021. The Secretary filed his
response brief on March 31, 2021, along with attachments to Mosby’s Medical
Dictionary and Black’s Medical Dictionary (exhibits A and B). Ms. Borden filed
her reply brief on April 7, 2021.
       On June 16, 2021, the undersigned issued an order, explaining he anticipates
either finding petitioner satisfies the severity requirement, or finding she has not
satisfied the severity requirement and dismissing the case. Nonetheless, the
undersigned permitted the parties to explain whether further oral testimony may
have been appropriate. See Order, issued June 16, 2021. Ms. Borden filed a status
report on June 30, 2021, indicating that she personally wanted to provide witness
testimony. A status conference was subsequently scheduled.
       During the July 7, 2021 status conference, the parties discussed holding a
hearing. Ms. Borden had argued that monitoring her thrombocytopenic purpura
constituted a residual effect, and that her bone biopsy constituted a surgical
intervention. See Pet’r’s Br. at 3-5. The Secretary disagreed with these arguments.
During the status conference, the Secretary questioned the value of petitioner’s
testimony given that the critical issue is a legal question rather than a factual one.
The undersigned noted that it was unclear how Ms. Borden’s personal testimony
would impact her case but stated that testimony from a treating doctor might be
informative. See Order, issued July 7, 2021. Accordingly, a hearing was
scheduled with the expectation that treating doctors may testify to help resolve the
issues. Id.
      A pre-hearing status conference was held on July 28, 2021. It was disclosed
that Ms. Borden would be the only witness testifying, as no treating doctors were
available or willing to testify. Order, issued July 28, 2021.
      The fact hearing was held on August 3, 2021. During the subsequent status
conference, the undersigned noted other pending cases might determine the
outcome of Ms. Borden’s case. At the time, the Federal Circuit was deliberating
                                          3
on Wright v. Sec’y of Health & Hum. Servs., and Leming v. Sec’y of Health &
Hum. Servs. had recently been remanded back to the Office of Special Masters
from the Court of Federal Claims. Due to these other cases, litigation was
temporarily stayed in Ms. Borden’s case. See Order, issued Sept. 10, 2021. The
Secretary filed a status report on December 6, 2021, providing updates on the
Wright and Leming cases.
      Petitioner’s counsel filed a death certificate for Ms. Borden on March 4,
2022. A status conference was scheduled for April 11, 2022, but then was
cancelled. On October 3, 2022, petitioner’s counsel filed letters of administration
showing Mr. David Borden had been appointed the personal representative of Ms.
Borden’s estate. The same day, petitioner moved to amend this case’s caption, and
the caption was amended the following day.
      As Leming and Wright appear to have concluded, this case is now ripe for
adjudication.
   II.   Summary of Evidence
       Medical records from Kaiser Permanent reflect that Ms. Borden received an
influenza vaccine on October 3, 2016. Exhibit 1 at 55; exhibit 10 at 1. Ms. Borden
presented to the emergency room approximately six and a half weeks later, on
November 18, 2016. Exhibit 3 at 93. Her chief complaint was of a petechial rash,
which started about a week prior. Id. Ms. Borden relayed that she was bruising
easily and was developing blood blisters. Id. The treaters noted a history of
Graves’ disease.
        During the November 18, 2016 visit, Ms. Borden had blood drawn for
further evaluation. Her platelet count was very low, at 3,000/mm3, whereas normal
counts are between 150,000/mm3 and 450,000/mm3. Id. at 95, 97. It was noted
that she was “severely thrombocytopenic.” Id. at 95. The note continues: “[l]ikely
this is due to idiopathic thrombocytopenia purpura. . . . Exact cause is unclear.” Id.
Ms. Borden received IVIG and prednisone, and her platelet counts subsequently
improved. She was discharged on November 23, 2016, with instructions to follow-
up with her primary care provider for repeat lab work. Id. at 127; exhibit 7 at 13.
       Her follow-up visit was on November 28, 2016. Blood work showed her
platelet count was dangerously low again. Exhibit 7 at 8, 11-12. The next day,
Ms. Borden was evaluated by Dr. Sujatha Nallapareddy, a hematologist. Exhibit 2
at 2. Dr. Nallapareddy recorded that her platelet count dropped to 1,000/mm3
despite prednisone and IVIG treatment. Id. at 3. He recommended hospitalization

                                          4
for further treatment. Id. So, Ms. Borden was hospitalized for four days and
received a platelet infusion, one round of IVIG and IV-Solumedrol, and a four-day
course of oral dexamethasone. Exhibit 3 at 375. A bone marrow biopsy and
aspiration were performed on December 2, 2016, to help determine the etiology of
Ms. Borden’s condition. Id. at 375, 503. An anesthesiologist was present for the
biopsy. Id. at 503. The procedures were performed in the Swedish Medical Center
minor procedures suite. Exhibit 5 at 8. Surgeons were consulted for a possible
splenectomy, but it was determined to not be necessary at that time. Exhibit 3 at
375. The platelet infusion, IVIG, and medications appeared helpful, as her platelet
count had risen to 81,000/mm3 by the time she was discharged on December 3,
2016. Id.
       Ms. Borden saw Dr. Nallapareddy for a follow-up visit on December 6,
2016. Exhibit 2 at 4. Her platelet count was 75,000/mm3. Id. at 5. They
discussed a splenectomy versus rituximab and other medications. Id. During a
follow-up visit on December 13, 2016, her platelet count was down to
28,000/mm3. Id. at 8-9. Dr. Nallapareddy interpreted her bone marrow biopsy
from the prior week as showing normal bone marrow with enlarged platelets. Id.
at 9. Ms. Borden returned to the emergency room on December 23, 2016, and her
platelet count was 72,000/mm3. Exhibit 3 at 764.
      On March 6, 2017, roughly five months after receiving the flu vaccination,
Ms. Borden was evaluated by Dr. David Schrier, a hematologist and oncologist, for
a second opinion regarding treatment of her condition. Exhibit 6 at 35. Dr.
Schrier’s assessment was that Ms. Borden was doing well, as she had no bleeding
or bruising and had been off therapy for a considerable period of time. Id. at 37.
Her platelet count was 182,000/mm3 that day. Id.
       Ms. Borden returned to Dr. Schrier’s office on November 13, 2017, where
she was evaluated by Dr. David Trevarthen.3 Id. at 29. She reported a rash on her
foot for the past month which appeared similar to the petechiae she noticed when
she was initially diagnosed with ITP. Id. Dr. Trevarthen advised her that the rash
appeared normal and was not consistent with petechiae. Id. at 31. Ms. Borden’s
platelet count was 195,000/mm3 at this visit, and she reported no unusual bleeding
or any worsening of bruising. Id. at 29, 31. Dr. Trevarthen noted that continuing
to periodically monitor her platelet count was reasonable. Id. at 31.

      3
          Dr. Schrier had left the practice by this date.
                                             5
      Ms. Borden was admitted to the hospital on June 18, 2018 and was
diagnosed with sepsis secondary to a parainfluenza infection. Exhibit 3 at 1037.
Her platelet count was 117,000/mm3. Id. at 1040. She returned to Dr. Trevarthen a
few days later, on June 20, 2018. Exhibit 6 at 14. At that visit, her platelet count
had recovered to 151,000/mm3. Id. at 16. Dr. Trevarthen opined her platelet count
“may have dipped in the setting of an acute severe illness.” Id.
       On September 11, 2018, Ms. Borden established a new primary care
provider, Barbara Doro. Exhibit 4 at 30. Ms. Doro advised Ms. Borden should get
her platelet levels checked every three months. Id. Ms. Borden’s platelet count
was 192,000/mm3 on October 10, 2018. Exhibit 6 at 11.
       Ms. Borden returned to see Dr. Trevarthen on January 7, 2019. Exhibit 6 at
4. The record notes Ms. Borden had “fairly extensive back surgery done [in] early
December.” Id. It further notes her platelet count went up to 435,000/mm3, above
the normal range, but Dr. Trevarthen opined this was probably reactive to the
surgery. Id. at 4, 6. The record notes her platelet count had returned to normal
levels by this visit. Id. at 6. Dr. Trevarthen advised Ms. Borden she should
probably continue to monitor her platelet count every 3 months, and then every 6
months if she had a good year. Id.
       Given the focus on the severity requirement, the parties did not discuss any
medical records after the January 7, 2019 visit. See Pet’r’s Br. at 3; Resp’t’s Br. at
5. Ms. Borden passed away on October 26, 2021. Exhibit 12. The death
certificate states she died of acute hypoxic respiratory failure and covid
pneumonia. Id.
   III.   Arguments Advanced in Briefs
       The parties were ordered to file briefs addressing whether Ms. Borden had
satisfied the severity requirement. See Order, issued Jan. 22, 2021. A summary of
the parties’ arguments follows.
      A. Ms. Borden’s Arguments
          1. Ms. Borden’s bone marrow biopsy constitutes a surgical intervention
       Ms. Borden underwent a bone marrow biopsy on December 2, 2016, and she
argues that procedure was a surgical intervention as defined by the Act. Pet’r’s Br.
at 3. In support of her contention, she notes an anesthesiologist was present for the
procedure. Id. She argues that the biopsy was a surgery that helped determine the

                                          6
proper course of treatment for her treatment-resistant ITP, and accordingly, the
surgery qualifies as a surgical intervention under the Act. Id. at 3-4.
      In support of her position, Ms. Borden cites Ivanchuk v. Sec’y of Health &
Hum. Servs., No. 15-357V, 2015 WL 6157016 (Fed. Cl. Spec. Mstr. Sept. 18,
2015) and Leming v. Sec’y of Health & Hum. Servs., No. 18-232V, 2019 WL
5290838.
       In her reply brief, Ms. Borden notes that her treating doctors knew she had
ITP. Pet’r’s Rep. at 1-2. Thus, she argues, the biopsy was not diagnostic but
instead performed “to determine the appropriate treatment for a case of ITP
refractory to standard treatment.” Id. at 2.
         2. Ms. Borden’s abnormal platelet count satisfies the severity
            requirement
       Ms. Borden concedes that continued monitoring of platelet counts based on a
petitioner’s own requests and without medical support would not satisfy the
severity requirement. However, she argues instead that her abnormal platelet
counts were sufficient to show severity. Pet’r’s Br. at 4-5.
       She distinguishes her case from Deese v. Sec’y of Health & Hum. Servs.,
No. 19-1127V, 2020 WL 7090213 (Fed. Cl. Spec. Mstr. Nov. 12, 2020). In Deese,
the petitioner developed ITP symptoms in early December 2018 and had normal
platelet counts by mid-April 2019. Id. at *3. Ms. Borden argues the claim in
Deese was dismissed, in part, because the petitioner’s request for continued
monitoring or petitioner’s own worry of possible ITP relapse failed to fulfill the
severity requirement. Pet’r’s Br. at 4. By contrast, Ms. Borden notes her platelet
levels continued to have fluctuations, evincing an ongoing problem. Id. She also
notes that her treating physicians advised her to monitor her platelet levels based
on those fluctuations. Id. Due to these differences, she argues her case should be
allowed to proceed so that experts may offer opinions. Id. at 5.
       Next, Ms. Borden argues that continual monitoring of symptoms of an
underlying condition satisfies the severity requirement. Id. For support, she cites
to Wright v. Sec’y of Health and Hum. Servs., 146 Fed. Cl. 608 (Fed. Cl. 2020).
She noted that an appeal had been filed in Wright. The Court of Federal Claims
had found that management of conditions satisfies the severity requirement if the
testing was conducted due to recurring symptoms. Id. at 612-15. Ms. Borden
compares her case to Wright in that her medical providers found continued
monitoring of her platelet counts to be a reasonable course. Pet’r’s Br. at 5. She

                                         7
further notes she had abnormal platelets on at least two occasions, validating her
treater’s recommendations.4 Id.
      In sum, Ms. Borden argues her platelet levels required monitoring due to
objective fluctuations, and these facts show her case meets the severity
requirement. Pet’r’s Rep. at 3-4. Because she had abnormal platelet counts that
required monitoring for more than six months, she has satisfied the severity
requirement.
      B. The Secretary’s Arguments
          1. Ms. Borden did not suffer direct ITP-related sequelae for six months
      At the outset, the Secretary notes that to satisfy the six-month sequelae
requirement, Ms. Borden must show residual effects or complications of her ITP
through at least April 3, 2017, six months after the vaccine administration date of
October 3, 2016. Resp’t’s Br. at 6. The Secretary argues Ms. Borden’s treating
hematologist noted she was asymptomatic with normalized platelet count on
March 6, 2017, and she required no further treatment after that date. Id. The
Secretary further argues Ms. Borden had no further ITP symptoms and required no
further treatment for her ITP.
       The Secretary acknowledges Ms. Borden had a low platelet count in June
2018 but notes that her physician attributed the decreased platelet count to the
sepsis / parainfluenza infection. Id. Furthermore, the Secretary points to the Act’s
qualifications and aids to interpretation (“QAI”). The QAI defines
thrombocytopenic purpura as clinically manifesting petechia, significant bruising,
or spontaneous bleeding, and by a serum platelet count less than 50,000/mm3. 42
C.F.R. § 100.3(c)(7) (2020). Although Ms. Borden’s platelet count was lower than
normal in June of 2018, it was above 50,000/mm3. Exhibit 3 at 1040.
          2. Ms. Borden’s bone marrow biopsy was not a surgical intervention
       The Secretary observes “surgical intervention” is not defined within the Act.
Resp’t’s Br. at 7; see 42 U.S.C § 300aa–33 (Definitions). Nor has the phrase been
defined by the Federal Circuit. The Secretary finds support for his argument that a
bone marrow biopsy is not a surgical intervention by referencing the legislative
history for the amendment that added the “surgical intervention” prong. Id. at 7-8.
The Secretary argues “surgical intervention” was added to the Act in 2000 to allow

      4
        In her reply brief, Ms. Borden emphasizes that further monitoring was not
due to her anxiety, but rather due to her doctor’s concerns. Pet’r’s Rep. at 2-3.
                                          8
for recovery in cases where a vaccinee develops intussusception, which often
requires abdominal surgery and typically does not persist for more than six months.
Resp’t’s Br. at 7.
      For further support, the Secretary cites several cases that have addressed the
Congressional intent and whether purely diagnostic procedures and surgeries are
considered “interventions” under the Act. These cases include Spooner v. Sec’y of
Health & Hum. Servs., No. 13-159V, 2014 WL 504728, at *5-6 (Fed. Cl. Spec.
Mstr. Jan. 16, 2014); Galvin v. Sec’y of Health & Hum. Servs., No. 20-313V, 2020
WL 4593163, at *4 (Fed. Cl. Spec. Mstr. July 6, 2020), aff’d 151 Fed. Cl. 789
(2021); and Stavridis v. Sec’y of Health & Hum. Servs., No. 07-261V, 2009 WL
3837479, at *5 (Fed. Cl. Spec. Mstr. Oct. 29, 2009).
       The Secretary also distinguishes the Ivanchuk case, in which the special
master held that the bone marrow biopsy in that case was a surgical intervention
because the medical records explicitly indicated the procedure was required to
institute treatment. 2015 WL 6157016, at *3. The special master carefully noted
that the decision “was not a finding that bone marrow biopsy constitutes a surgical
intervention in all circumstances.” Id.
       In sum, the Secretary argues Ms. Borden’s bone marrow biopsy and
aspiration were diagnostic procedures rather than an intervention to treat a
condition. The Secretary analogizes the procedure to the arthrocentesis in Galvin
and the lumbar puncture in Spooner. Resp’t’s Br. at 12.
          3. Ms. Borden had normal lab results
       The Secretary disputes Ms. Borden’s argument that continued monitoring of
her platelet count due to abnormal results satisfies the six-month sequelae prong of
the severity requirement.5 Resp’t’s Br. at 12. For support, the Secretary discusses
Crabbe v. Sec’y of Health & Hum. Servs., No. 10-762V, 2011 WL 4436724 (Fed.
Cl. Spec. Mstr. Aug. 26, 2011). In Crabbe, the special master ruled that “testing
for a possible recurrence [of ITP] is not a ‘residual effect’ within the meaning of
the statute.” Id. at *5. In so doing, the special master determined that an increased
risk of an injury’s recurrence is not sufficient to establish a “residual effect” under
the Act; rather, the symptoms need to actually manifest to constitute a residual
effect of that injury. Id. at *4-5. The Crabbe rationale was adopted by the special

      5
        Additionally, the Secretary notes that the petition was dismissed in Deese
due to failure to prosecute and insufficient proof.

                                           9
master in Wright. No. 16-498V, 2019 WL 1061472, at *11 (Fed. Cl. Spec. Mstr.
Jan 18, 2019).6 The special master in Wright reasoned that blood tests “were done
only to test for potential recurrence of [the child’s] ITP, not to manage existing
symptoms or sequelae thereof.” Id.
       Next, the Secretary notes that although “residual effects” and
“complications” are not defined in the Act, the terms have been interpreted in other
cases by using standard medical definitions. Resp’t’s Br. at 13-14. He cites
multiple cases for support, including Parsley v. Sec’y of Health & Hum. Servs.,
No. 08-781V, 2011 WL 2463539 (Fed. Cl. Spec. Mstr. May 27, 2011). In Parsley,
the special master used a medical dictionary to define a “residual effect” as
something left behind or resulting from an illness, disability, injury, or condition.
Parsley, 2011 WL 2463539, at *16. Thus, the Secretary argues that lab work
which reveals normal platelet counts in individuals previously diagnosed with ITP
should not be relied on in determining whether a petitioner satisfies the severity
requirement. Resp’t’s Br. at 14. Furthermore, he notes the sequelae clause
requires a petitioner to “suffer” and a normal platelet count indicates a lack of
suffering. Id. The Secretary also distinguishes the facts of this case from the Court
of Federal Claim’s ruling in Wright. See Resp’t’s Br. at 14-15.
   IV.    Analysis
       To prove entitlement under the Act, petitioners must demonstrate their injury
is sufficiently severe. This is known as the “severity requirement.” Two prongs of
the severity requirement are at issue in this case. Petitioners can demonstrate
severity by showing the vaccinee “suffered the residual effects or complications”
of the vaccine-related injury “for more than 6 months after the administration of
the vaccine[.]” 42 U.S.C. § 300aa–11(c)(1)(D)(i). Alternatively, petitioners can
show the vaccinee’s injury “resulted in inpatient hospitalization and surgical
intervention.” Id. at § 300aa–11(c)(1)(D)(iii). Such showings must be supported
by a preponderance of the evidence, substantiated by medical records or medical
opinion. 42 U.S.C. § 300aa–13(a)(1).
       The Federal Circuit has interpreted the “residual effects” clause as a
limitation of compensation to individuals that are seriously injured by a vaccine.
Cloer v. Sec’y of Health & Hum. Servs., 654 F.3d 1322, 1335 (Fed. Cir. 2011),
cert. denied, 132 S. Ct. 1908 (2012). Congress added the “surgical intervention”
      6
       At the time the Secretary wrote his brief, Wright had been reversed by the
Court of Federal Claims, 146 Fed. Cl. 608 (2020), and was on appeal to the Court
of Appeals for the Federal Circuit. A decision has since issued, discussed below.
                                         10
prong in 2000, and the legislative history indicates how to interpret that clause.
Proceedings and Debates of the 106th Congress, First Session, 145 Cong. Rec.
S15213-03 (November 19, 1999), 1999 WL 34977042.
      A. Relevant Precedent
       While the parties were developing the evidence and arguments in this case,
two cases were being litigated which directly addressed the proper construction of
“residual effects” and “surgical intervention.” Litigation was stayed in this matter
until those cases were resolved. Below is a summary of those cases.
             1. Leming v. Secretary of Health and Human Services
       In Leming, the special master initially found the petitioners’ daughter, A.L.,
was entitled to compensation because she suffered from immune thrombocytopenic
purpura within weeks of receiving a measles-mumps-rubella-varicella vaccine.
The special master found that the injury resulted in hospitalization and a “surgical
intervention,” thus satisfying the severity requirement. Leming v. Sec’y of Health
& Hum. Servs., No. 18-232V, 2019 WL 5290838 (Fed. Cl. Spec. Mstr. July 12,
2019). The Secretary filed a motion for review and argued the special master
improperly interpreted “surgical intervention” within the context of the Act and the
legislative history. On review, the Court of Federal Claims disagreed with the
special master’s analysis that A.L.’s bone marrow biopsy was a surgical
intervention performed “to institute treatment rather than diagnose” and remanded
the case in light of the finding that A.L. did not undergo a surgical intervention.
Leming, 154 Fed. Cl. 325, 334-35 (June 16, 2021) (“Leming I”).
       On remand, the special master found that A.L.’s injury did not satisfy the
severity requirement and dismissed the claim. 2022 WL 3371016 (Fed. Cl. Spec.
Mstr. Jan. 26, 2022). The petitioners’ motion for reconsideration was denied.
2022 WL 3444742. The Court of Federal Claims then denied the petitioners’
second motion for review. --- Fed. Cl. ---, 2022 WL 3723131 (2022) (“Leming
II”). The arguments raised by petitioners in Leming II included claiming the
special master was arbitrary and capricious for determining (1) the presence of
giant platelets was not a residual effect of ITP and (2) that the child was not
restricted from receiving immunizations until her sixth birthday. Id. at *11-16.
             2. Wright v. Secretary of Health and Human Services
      A similar issue arose in the Wright case. In Wright, the petitioner alleged
her son, B.W., developed immune thrombocytopenic purpura after receiving a
measles-mumps-rubella vaccine. No. 16-498V, 2019 WL 1061472 (Fed. Cl. Spec.

                                          11
Mstr. Jan. 18, 2019). A few months later, B.W.’s blood tests indicated a normal
platelet count, and B.W.’s pediatrician opined the condition had resolved. Id. at
*2. More than six months after the vaccination, B.W. returned to his pediatrician
multiple times due to bruising; however, blood tests from those visits revealed
platelet counts well about 50,000/mm3 and within normal limits. Id. at *2-3.
Holding that testing for a possible recurrence of ITP was not a residual effect
within the meaning of the Act, the special master dismissed the petition for failure
to satisfy the severity requirement. Id. at *11-13.
       Ms. Wright filed a motion for review. The Court of Federal Claims ruled
that the special master erred as a matter of law, reasoning that “ordering platelet
counts when a patient with a history of ITP is presented with bruising” was “within
the doctor’s reasonable standard of care” and that the testing was “causally
connected to the vaccine injury[.]” 146 Fed. Cl. 608, 614-15 (2019). In essence,
the Court of Federal Claims found that testing for a condition should be
compensated if the testing is connected to an underlying vaccine injury and the
testing is prompted by subsequent symptoms of the injury. After the case was
remanded and damages were awarded, the Secretary appealed.
       On appeal, the Court of Appeals for the Federal Circuit reversed. It held that
relatively non-invasive monitoring was not a “residual effect” under the severity
requirement. 22 F.4th 999, 1005-06 (Fed. Cir. 2022). The Court also held that
bruising, after blood tests indicated that ITP had resolved, was not a “residual
effect” under the severity requirement. Id. at 1005.
      B. Ms. Borden has not satisfied the severity requirement
       For the reasons explained below, Ms. Borden has not demonstrated her
injury was sufficiently severe to justify entitlement under the Act.
       Ms. Borden received an influenza vaccine on October 3, 2016. Exhibit 1 at
55. To demonstrate she suffered the residual effects of an injury from that vaccine
for more than 6 months, Ms. Borden would need to show residual effects through
at least April 3, 2017, or that she underwent a surgical intervention.
       About six and a half weeks after the vaccine, Ms. Borden arrived at an
emergency room with a petechial rash, which started about a week prior. Exhibit 3
at 93. She was bruising easily and was developing blood blisters. Id. Her platelet
count was extremely low, at 3,000/mm3, well below normal limits. Id. at 95, 97.
The treating physician opined she suffered from idiopathic thrombocytopenia
purpura. Id. at 95.

                                         12
      On November 28, 2016, Ms. Borden’s platelet court was concerning low
once again. Exhibit 7 at 8, 11-12. Per recommendation by Dr. Nallapareddy she
was hospitalized and received a platelet infusion and other treatment protocols.
Exhibit 3 at 375.
      A few days later, on December 2, 2016, a bone marrow biopsy and a bone
marrow aspiration were performed on Ms. Borden. Id. at 375, 503. The parties
dispute whether these procedures constitute a “surgical intervention.” As
discussed below in Section IV.B.1, these procedures are not surgical interventions
within the meaning of the Act.
       Ms. Borden’s platelet count was 81,000/mm3 when she was discharged on
December 3, 2016. Id. at 375. On December 6, 2016, Ms. Borden’s platelet count
was 75,000/mm3. Exhibit 2 at 5. Soon after, on December 13, 2016, her platelet
count fell to 28,000/mm3. Id. at 8-9. Dr. Nallapareddy interpreted her bone
marrow biopsy from the prior week as showing normal bone marrow with enlarged
platelets. Id. at 9. Ms. Borden had a platelet count of 72,000/mm3 when she
returned to the ER on December 23, 2016. Exhibit 3 at 764.
       Dr. Schrier assessed that Ms. Borden was doing well on March 6, 2017, as
she had no recent bleeding or bruising, and her platelet count was 182,000/mm3
that day. Exhibit 6 at 35-37. This test, approximately five months after her flu
vaccine, suggests that her condition had resolved. This finding is bolstered by the
lack of visits to doctors or emergency rooms for the next several months.
       On November 13, 2017, Ms. Borden returned to Dr. Schrier’s office, and
was evaluated by Dr. David Trevarthen. Id. at 29. Though she was concerned
about a rash that appeared similar to a petechiae, Dr. Trevarthen advised her that
the rash appeared normal. Id. at 31. Ms. Borden’s platelet count was normal at
this visit, at 195,000/mm3. Id. at 29, 31. There are no additional medical records
recording a platelet count of below 100,000/mm3, let alone below 50,000/mm3.7
          1. Ms. Borden’s bone marrow biopsy and aspiration were not surgical
             interventions
      In Leming I, the Court of Federal Claims held that A.L.’s bone marrow
biopsy and aspiration were not “surgical intervention[s].” 154 Fed. Cl. at 333-35.
The Court in Leming I determined that the bone marrow biopsy and aspiration
performed on A.L. qualified as surgical procedures, but also ruled that the bone
      7
       See 42 C.F.R. § 100.3(c)(7) (2020) (requiring a platelet count of less than
50,000/mm3 to evince thrombocytopenic purpura).
                                         13
marrow aspiration and biopsy could not be characterized as surgical interventions
under the Act. Id. at 332-33. This distinction was reached in part due to dictionary
definitions; the Court recognized than an “intervention” is intended to or does in
fact alter the course of a disease. Id. at 333. As such, the Court found “the term
‘surgical intervention’ is best read to include only those surgical procedures that
are administered to directly treat a condition once it has been diagnosed.” Id. at
333. Thus, purely diagnostic surgical procedures are not interventions.
       For support, the Court of Federal Claims cites to and interprets the
legislative history of the 2000 amendment, which birthed the “surgical
interventions” clause. Id. at 333-34; see 1999 WL 34977042. In essence, the
clause was added to address cases in which individuals developed intussusception
after receiving a rotavirus vaccine. That condition, when properly treated, would
not result in 6 months of injury or death, hence the justification to modify the Act
to provide compensation for that vaccine-induced injury.
       The undersigned finds the reasoning in Leming I to be persuasive. When
Congress added the “surgical intervention” language, it was not intended to
mitigate the Act’s severity requirement such that any surgical intervention would
become equivalent to six months of residual effects or sequela. The legislative
history states:
             To our knowledge, the amendment would only apply to
             circumstances under which a vaccine recipient suffered
             from intussusception as a result of administration of the
             rotavirus vaccine. The amendment is not intended to
             expand jurisdiction to other vaccines listed in the
             Program’s Vaccine Injury Table.
1999 WL 34977042.
       The bone marrow biopsy and aspiration Ms. Borden received on December
2, 2016 were not “surgical interventions.” The procedures, even if considered
surgeries, were performed to help determine the etiology of Ms. Borden’s
condition rather than provide treatment. This is quite different from the
splenectomy that was considered by the surgeons. Furthermore, the legislative
history makes clear that “surgical intervention” was intended to have a limited
application. As such, the procedures Ms. Borden received, even if considered
surgeries, do not satisfy the “surgical intervention” prong of the severity
requirement.

                                         14
         2. Ms. Borden’s abnormal platelet counts do not satisfy the severity
            requirement
       Ms. Borden attempts to argue she had abnormal platelet counts more than
six months after her vaccine, and that the abnormal results and need for monitoring
demonstrate she satisfied the severity requirement. For the reasons noted below,
this argument is not persuasive.
     Ms. Borden received the flu vaccine on October 3, 2016. She became
thrombocytopenic and had dangerously low platelet counts. However, about five
months later, in March of 2017, Ms. Borden’s platelet levels had returned to a
normal count of 182,000/mm3. Her platelet levels thereafter never fell to
dangerously low levels.
       The next time she went to a hospital was about eight months later, in
November of 2017, and her platelet count was 195,000/mm3 at that visit. In June
of 2018, Ms. Borden’s platelet count fell below 150,000/mm3, down to
117,000/mm3. Arguably, this was abnormal count. However, her treating doctors
felt that this was due to a parainfluenza infection and/or sepsis. Furthermore, this
platelet count does not evince thrombocytopenia purpura, as defined in the Vaccine
Table, because it is not less than 50,000/mm3.
      Ms. Borden also had an abnormally high platelet count of 435,000/mm3 after
a back surgery, which her physician thought was caused by the surgery. But, an
elevated platelet count is precisely the opposite of thrombocytopenia.
       Based on these objective tests, it seems more likely that Ms. Borden had an
acute form of thrombocytopenia rather than a relapsing or chronic version of the
disease. Her blood work strongly suggests her condition resolved within six
months. Although it may have been reasonable for Ms. Borden to continue to get
blood tests, the risk of a recurrence of an injury without an actual recurrence is not
a residual effect within the meaning of the Act. Crabbe, 2011 WL 4436724, at *5.
Furthermore, relatively non-invasive monitoring is not a “residual effect” under the
Act. Wright, 22 F.4th at 1005-06.
   V.    Conclusion
      Ms. Borden has not demonstrated that her condition has satisfied the severity
requirement. Without such a showing, she cannot establish entitlement to
compensation. Accordingly, the Clerk’s Office is instructed to enter judgment in
accordance with this decision unless a motion for review is filed. Information

                                          15
about filing a motion for review, including the deadline, can be found in the
Vaccine Rules, available through the Court’s website.

      IT IS SO ORDERED.

                                       s/Christian J. Moran
                                       Christian J. Moran
                                       Special Master

                                         16